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Data set presented in this article is related to the research paper
entitled “Effect of amaranth proteins on the RAS system. In vitro,
in vivo and ex vivo assays”, available in Food Chemistry [1]. In this
article, we evaluated the effect on systolic blood pressure of
spontaneously hypertensive rats (SHR) of different samples with
amaranth proteins/peptides. The effect of these samples on RAS
system was evaluated using in vitro and ex vivo assays. The con-
centration of renin and angiotensin converting enzyme (ACE) was
evaluated using two commercial ELISA kits. Renin concentration
was estimated through a direct immunoassay and ACE concen-
tration with an immunoassay based on a competitive inhibition. In
addition, the ACE inhibitory activity in plasma was evaluated using
a spectrophotometric assay according to [2]. Ex vivo experiments
were done with thoracic aorta extracted during the surgical pro-
cedure employed to obtain blood samples according to [3]. Data
presented in this article recollect a very extensive work on how can
be affect the RAS system in SHR model using amaranth protein/
peptides as potential antihypertensive samples. These data couldj.foodchem.2019.125601.
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Data describes the effect of amaranth protein/peptides on RAS system inquiring into themechanism
of action of these samples using in vitro, in vivo and ex vivo approaches [1].
Treatment groups were:
1. GW: Negative control group. Animals treated with water, which did not receive amaranth proteins.
2. GC: Captopril group. Animals treated with captopril, an ACE inhibitor.
3. GA: Aliskiren group. Animals treated with aliskiren, a renin inhibitor.
4. GAPI: API group. Animals treated with amaranth protein isolated (API).
5. GAH: AH group. Animals treated with amaranth protein hydrolysate (AH).
6. GVIKP: VIKP group. Animals treated with the synthetic peptide VIKP.
7. GE: w/o Emulsion group. Animals treated with w/o emulsion.
8. GEþVIKP: w/o Emulsion þ VIKP group. Animals treated with w/o emulsion added with VIKP.
In order to compare mean values, a one way analysis of variance (ANOVA) multiple comparisons
was applied. The critical significance level was set at p < 0.05. All samples were compared to GW
(negative control group).
Table 1 shows the reduction in SBP values exerted in each experimental group. Datawere expressed
as the decrease of SBP in mmHg of animals 3 h after the administration of each sample with respect to
the SBP measured at the beginning of the experiment (SBP3h-SBP0hi). DP values are presented as
mean ± SEM. Animals belonging to the GE and GEþVIKP groups showed themost significant reduction in
the SBP reaching reduction values of 42 ± 2 mmHg and 35 ± 2 mmHg respectively. The administration
of API, AH or VIKP in water as vehicle (GAPI, GAH y GVIKP groups) caused a reduction in SBP values that
was significantly lower than those observed in the groups mentioned above (25 ± 14 mmHg,
26 ± 3 mmHg and 21 ± 3 mmHg respectively.)
Table 2 shows ACE plasma concentration of different groups assayed. This ELISA immunoassay is
based on a competitive inhibition. Calibration curve was calculated according to the manufacturer's
directions and the values are as follows: y ¼ 0.7089 e (0.001405.X) þ 0.107 where “y” means OD at
450nm and “x” is ACE sample concentration in mg/ml. It can be observed that GW group presented
extremely low values of ACE levels (0.17± 0.02 mg/ml), whereas ACE concentration in GC GAGE y GEþVIKP
groups were 13.6e25.8 times higher than control group. API, AH and VIKP (GAPI,GAH,GVIKP groups
respectively) induced an increase in the ACE levels that was 7.6 to 5.3 times higher than control group
(1.3 ± 0.2 mg/ml, 0.90 ± 0.3 mg/ml and 1.1 ± 0.3 mg/ml respectively. p < 0.05). The same trend has been
observed in studies evaluating synthetic drugs in hypertension treatments [4,5].
Table 3 shows renin plasma concentration in the different samples assayed. Calibration curve ob-
tainedwas y¼ 0.005xþ 0.008where “y”means OD at 450 nm and “x” represented renin concentration
in pg/ml. Only the GA, GAPI and GAH groups presented differences in plasma renin levels, as compared to
GW group. No differences were found in the levels of this enzyme between GC, GE, GVIKP and GEþVIKP
groups and the control group GW.
Table 4 shows % ACE activity/mg ACE in plasma collected after treatments. Data are expressed as
relative to 100% ACE activity to water control group (GW). The lowest activity values (4e7% active ACE/
mg ACE) corresponded to groups GC, GA, GE and GEþVIKP, whereas the highest activity values were found
in GVIKP, GAH and GAPI groups, which presented 20e13% active ACE/mg ACE. The administration of
different samples decreases the enzymatic activity of ACE, together with an increase in plasma levels
(Table 2), probably to counter balance the inhibitory effect exerted by the hypotensive peptides.
Table 5 shows the contractile activity determined in presence of potassium ions. Contractile force
was higher in GW, GC and GA groups (roughly 0.45 g/mg), whereas this activity was significantly lower
in the animals belonging to groups GAPI, GVIKP, GEþVIKP, GAH and GE (0.34e0.29 g/mg). Upon treating
aorta rings with physiological concentrations of norepinephrine, statistically differences were
observed in GVIKP and GEþVIKP groups.
Table 1
Systolic blood pressure before and after treatment. DP (SBP3h-SBP0hi) values are presented as mean ± SEM.
Treatment group SBP (mm Hg)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
GW 196 281 215 190 188 206
176 280 193 195 177 196
200 273 244 202 170 201
average 191 278 217 196 178 201
post intragastric administration
201 314 208 228 167 188
186 283 179 222 152 187
196 244 156 203 162 250
average 194 280 181 218 160 208
DP ¼ SBP3h-SBP0hi 4 2 36 22 18 7
DP average -3a
SEM 8
GA 196 185 195 196
197 183 187 192
190 186 185 193
average 194 185 189 194
post intragastric administration
145 156 139 139
147 154 140 135
152 150 145 140
average 148 153 141 138
DP ¼ SBP3h-SBP0h 46 31 48 56
DP average ¡45b
SEM 5
GC 208 205 e 205
199 205 e 193
199 205 e 183
average 202 205 194
post intragastric administration
166 171 e 168
159 173 e 171
162 177 e 163
average 162 174 167
DP ¼ SBP3h-SBP0h 40 31 26
DP average ¡32b
SEM 4
GAPI 166 162 197 180 259
160 166 208 187 238
159 168 204 190 234
average 162 165 203 186 244
post intragastric administration
153 155 136 140 179
145 157 147 154 173
158 154 152 162 182
average 152 155 145 152 178
DP ¼ SBP3h-SBP0h 10 10 58 34 66
DP average ¡35b
SEM 12
GAH 181 184 184 162 159 174 203 199 208 183 162 168 170 195
184 184 186 159 161 179 192 184 198 173 166 182 181 191
average 182 177 188 158 164 177 191 173 199 169 160 177 182 185
182 182 186 160 161 177 195 185 202 175 163 176 178 190
post intragastric administration
145 166 165 145 140 156 167 e 176 146 123 148 150 146
156 159 166 156 145 158 161 e 177 148 116 141 158 148
156 168 158 151 146 155 168 e 177 146 129 145 157 139
average 152 164 163 151 144 156 165 e 177 147 123 145 155 144
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Table 1 (continued )
Treatment group SBP (mm Hg)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
DP ¼ SBP3h-SBP0h 30 17 23 9 18 20 30 e 25 28 40 31 23 46
DP average ¡26b
SEM 3
GVIKP 209 223 223 221 205 208 201 201
206 222 201 218 208 209 199 203
205 219 208 219 208 205 203 206
average 207 221 211 219 207 207 201 203
post intragastric administration
188 193 183 188 200 193 182 179
191 192 181 190 201 183 181 177
195 199 177 195 205 188 180 185
average 191 195 180 191 202 188 181 180
DP ¼ SBP3h-SBP0h 15 27 30 28 5 19 20 23
DP average ¡21b
SEM 3
GE 188 181 187 183 181 178 190 192
186 183 182 187 179 180 196 198
191 187 202 185 179 177 191 196
average 188 184 190 185 180 178 192 195
post intragastric administration
151 140 142 145 144 142 157 148
145 143 142 147 142 141 146 145
142 145 149 142 148 145 145 141
average 146 143 144 145 145 143 149 145
DP ¼ SBP3h-SBP0h 42 41 46 40 35 36 43 51
DP average ¡42b
SEM 2
GEþVIKP 173 155 153 151 171 169 171
175 169 177 174 175 177 175
169 171 175 173 173 174 173
average 172 165 168 166 173 173 173
post intragastric administration
132 138 132 138 132 137 135
135 136 135 137 134 132 134
137 134 136 135 137 135 136
average 135 136 134 137 134 135 135
DP ¼ SBP3h-SBP0h 38 29 34 29 39 39 38
DP average ¡35b
SEM 2
S. Suarez et al. / Data in brief 29 (2020) 105168 52. Experimental design. Materials and methods
2.1. Samples
The following samples were used for in vivo assays:
- Amaranth protein isolate (API) and hydrolysate (AH) prepared from Amaranthus hypochondriacus as
described elsewhere [2]. The protein content was 87 ± 1 and 57 ± 2% w/w w.b. for API and AH
respectively.
- VIKP peptide, which is a synthetic peptide from 11S amaranth protein. This peptide has inhibitory
activity on ACE [6].
- O/W 20:80 emulsions prepared with sunflower oil and 1:1 protein mixture of API and AH at pH 2
with a total protein concentration of 2% w/v with or without VIKP peptide [(API50 þ AH50)-2%þ
VIKP and (API50 þ AH50)-2%, respectively].
Table 2
Plasma ACE concentration at the end of the 3 h treatment. Values are presented as mean ± SEM.
Treatment group Rat OD450 (nm) mg/ml Average SD SEM









GC 1 0.089 2.50 2.50b 0 0
2 0.078 2.50
3 0.09 2.50
GAPI 1 0.134 1.16 1.35b 0.52 0.3
2 0.11 1.94
3 0.156 0.95





















S. Suarez et al. / Data in brief 29 (2020) 1051686Emulsions were prepared according to [2]. Emulsions were frozen at 80 C, lyophilized and
resuspended as required. Before administration, the resuspended emulsions were homogenized with a
magnetic stirring bar.
- Commercial ACE and renin inhibitors (captopril and aliskiren, respectively) were employed as
positive controls.
2.2. In vivo assays
2.2.1. Indirect measurement of blood pressure
The systolic blood pressure was measured according to [3]. In order to determine baseline values,
blood pressure values were recorded at least three times on different days for each rat. After recording
Table 3
Plasma renin concentration at the end of the 3 h treatment. Values are presented as mean ± SEM.
Treatment group Rat OD450 (nm) pg/ml Average SD SEM
GW 1 0.279 0.305 54.2 59.4 42.4a 9.9 3.1
2 0.183 0.171 35 32.6
3 0.252 0.221 48.8 42.6
4 0.223 0.239 43 46.2
5 0.158 0.171 30 32.6
GA 1 0.199 0.175 38.2 33.4 34.2b 4.7 1.9
2 0.216 0.16 41.6 30.4
3 0.166 0.158 31.6 30
GC 1 0.193 0.178 37 34 35.1a 3.4 1.4
2 0.176 0.159 33.6 30.2
3 0.21 0.185 40.4 35.4
GAPI 1 0.13 0.151 24.4 28.6 34.0b 7.3 2.5
2 0.228 0.222 44 42.8
3 0.137 0.177 25.8 33.8
4 0.193 0.184 37 35.2
GAH 1 0.157 0.155 29.8 29.4 30.7b 4.1 1.9
2 0.193 0.152 37 28.8
3 0.141 0.143 26.6 27
4 0.194 0.157 37.2 29.8
GVIKP 1 0.192 0.15 36.8 28.4 34.9a 4.7 1.9
2 0.221 0.17 42.6 32.4
3 0.18 0.181 34.4 34.6
GE 1 0.207 0.167 39.8 31.8 35.1a 4.7 1.9
2 0.163 0.159 31 30.2
3 0.212 0.192 40.8 36.8
GEþVIKP 1 0.237 0.209 45.8 40.2 36.3a 9.6 3
2 0.192 0.175 36.8 33.4
3 0.236 0.227 45.6 43.8
4 0.124 0.115 23.2 21.4
S. Suarez et al. / Data in brief 29 (2020) 105168 7the last baseline blood pressure value, an aqueous suspension of each samplewas administered to each
animal. Three hours after the administration, blood pressure values were recorded with a tail cuff and a
pulse sensor (NarcoBiosystems, Houston, TX).
2.2.2. Determination of plasma ACE and renin concentrations
A commercial ELISA kit (Rat Angiotensin converting enzyme MBS703086, MyBioSource, CA, USA)
was employed to determine ACE concentration according to manufacturer's directions. This immu-
noassay is based on a competitive inhibition. Briefly, microtitre plates are coated with ACE. Samples
and standards are incubated together with an anti-ACE HRP-labeled conjugate to generate the
competition. Plasma renin concentrationwas determined with a commercial ELISA kit (Rat renin ELISA
kit MBS041519 MyBioSource) following the manufacturer's directions. This immunoassay is a direct
ELISA, which has an analytical measurement range of 6.25e200 pg/ml. The final colour reaction was
read in a microtiter plate reader (Biotek Synergy HT, Winooski, VT, USA) at 450 nm.
2.2.3. Determination of plasma ACE activities
ACE-inhibitory activity was assayed according to [2]. Briefly, to determine the enzymatic activity, 50
ml of buffer [0.2M sodium borate pH 8.3; 2M NaCl), 25 ml of milli Q water, 25 ml of the commercial
enzyme (maximum activity control)], or plasma samples were incubated with 100 ml of synthetic
substrate (HHL) at 37 C for 30 min. The reactionwas stopped by heating the mixture over awater bath
at 90 C for 15 min. After cooling, 600 ml of 0.2M potassium pH 8.2 and 515 ml of colour reagent, which
reacts with the hippuric acid generated during the enzymatic reaction, were added and stirred
Table 4
Plasma ACE activity. These data are expressed as relative to 100% ACE activity to water control group (Cw). Data are presented as
mean ± SEM.
Treatment group Rats DO382(nm) mg enzyme DO382/mg enzyme Activity (%)/mg enzyme Average SD SEM
GW 1 0.794 0.773 0.0037 214.6 208.8 104.5 101.7 100.0a 4.8 0.01
2 0.790 0.725 0.0037 213.4 196.0 103.9 95.5
3 0.689 0.752 0.0037 186.3 203.3 90.7 99.0
4 0.785 0.798 0.0037 212.2 215.8 103.4 105.1
5 0.768 0.721 0.0037 207.7 195.0 101.2 95.0
GA 1 0.845 0.771 0.0519 16.3 14.9 7.8 7.1 7.3b 0.2 0.01
2 0.786 0.781 0.0519 15.1 15.0 7.3 7.2
3 0.791 0.781 0.0519 15.2 15.0 7.3 7.2
4 0.771 0.801 0.0519 14.9 15.4 7.1 7.4
GC 1 0.733 0.790 0.0625 11.7 12.6 5.6 6.1 5.8b 0.2 0.01
2 0.764 0.785 0.0625 12.2 12.6 5.9 6.0
3 0.710 0.756 0.0625 11.4 12.1 5.5 5.8
GAPI 1 0.723 e 0.0338 21.4 e 10.3 10.7b 0.3 0.01
2 0.761 e 0.0338 22.5 e 10.8
3 0.757 0.785 0.0338 22.4 23.2 10.8 11.2
4 0.748 0.739 0.0338 22.1 21.9 10.6 10.5
GAH 1 0.747 0.756 0.0218 34.3 34.7 16.5 16.7 16.9b 0.5 0.01
2 0.716 0.752 0.0218 32.8 34.5 15.8 16.6
3 0.791 0.747 0.0218 36.3 34.3 17.5 16.5
4 0.801 0.776 0.0218 36.7 35.6 17.7 17.2
5 0.776 0.771 0.0218 35.6 35.4 17.2 17.0
GVIKP 1 0.794 0.799 0.0218 36.4 36.7 17.5 17.6 17.7b 0.5 0.01
2 0.809 0.799 0.0218 37.1 36.7 17.8 17.6
3 0.744 0.819 0.0218 34.1 37.6 16.4 18.1
4 0.804 0.799 0.0218 36.9 36.7 17.7 17.6
5 0.840 0.814 0.0218 38.6 37.3 18.5 17.9
6 0.824 0.809 0.0218 37.8 37.1 18.2 17.8
7 0.799 0.785 0.0218 36.7 36.0 17.6 17.3
GE 1 0.742 0.765 0.0625 11.9 12.2 5.7 5.9 5.8b 0.1 0
2 0.785 0.790 0.0625 12.6 12.6 6.0 6.1
3 0.742 0.756 0.0625 11.9 12.1 5.7 5.8
4 0.751 0.756 0.0625 12.0 12.1 5.8 5.8
5 0.765 0.770 0.0625 12.2 12.3 5.9 5.9
6 0.742 0.747 0.0625 11.9 12.0 5.7 5.8
7 0.725 0.775 0.0625 11.6 12.4 5.6 6.0
GEþVIKP 1 0.785 0.684 0.0573 13.7 11.9 6.6 5.7 6.4b 0.3 0.01
2 0.770 0.785 0.0573 13.4 13.7 6.5 6.6
3 0.775 0.761 0.0573 13.5 13.3 6.5 6.4
4 0.756 0.765 0.0573 13.2 13.4 6.4 6.4
5 0.821 0.765 0.0573 14.3 13.4 6.9 6.4
S. Suarez et al. / Data in brief 29 (2020) 1051688vigorously with a vortex and then centrifuged for 10 min at 20 C and 3000g. The absorbance was
measured at 382 nm in a spectrophotometer (Beckman DU 650). The reaction blank was obtained by
incubating the synthetic substrate with neither the plasma samples nor the enzyme, completing the
reaction volumewith milli Q water. Reaction blanks without the substrate (HHL was replaced by 100 ml
of borate buffer) and containing plasma samples were also included. Controls containing plasma
samples and captopril were also assayed.
2.2.4. Ex vivo experiments
During the surgical procedure employed to obtain blood samples, the thoracic aorta was resected
and placed in saline solution bubbled with 5% CO2 and 95% O2. The adjacent connective tissue was
carefully removed avoiding distention of the vessel and damage to the endothelium. The aorta was
Table 5
Effect of different samples on isolated aortic rings contracted by exposure to a high concentration of: Potassium ion (80mM) and
Norepinephrine (106 M). Fb1 (g): basal force before K addition. Fb2 (g): basal force before N addition. Fc (g): contractile force. N:
norepinephrine. K: potassium ion. AW: aorta weight. Data are presented as mean ± SEM.
Treatment group Rats Fb1 (g) Fc K (g) Fb2 (g) Fc N (g) AW (mg) Fc K (g/mg) Fc N (g/mg)
Gw 1 0 1.15 0.18 2.06 2.69 0.428 0.699
2 0.07 1.28 0.22 1.79 2.33 0.519 0.674
3 0.08 0.8 0.14 1.2 2.24 0.393 0.473
4 0.13 1.08 0.12 1.25 3.4 0.356 0.332
5 0.03 1.18 0.02 1.09 3.21 0.377 0.333




GA 1 0.042 1.113 0.056 1.253 3.47 0.333 0.345
2 0.07 1.015 0.007 1.239 2.00 0.543 0.623
3 0.021 1.113 0.0035 1.253 2.42 0.451 0.516




GC 1 0.03 1.68 0.15 1.29 3.95 0.418 0.365
2 0.07 1.54 0.59 1.85 3.45 0.426 0.365




GAPI 1 2.1 2.95 2.1 3.48 2.56 0.332 0.539
2 1.98 2.67 2.19 3.21 3.12 0.221 0.327
3 2.08 3.29 2.29 3.73 3.94 0.307 0.365
4 0.1 0.9 0.3 1.2 2.85 0.281 0.316
5 0 0.9 0.1 1.1 1.9 0.474 0.526




GAH 1 0.1 1.2 0.4 1.5 2.50 0.52 0.44
2 0.1 1.5 0.3 1.8 2.98 0.537 0.503
3 0 0.9 0.2 1.1 2.38 0.378 0.378
4 0.02 0.5995 0.275 0.8085 2.06 0.301 0.526
5 0.06 0.6655 0.06 0.9075 1.90 0.319 0.509
6 0.04 0.8525 0.099 1.089 1.91 0.467 0.622
7 0.07 0.528 0.165 0.759 2.24 0.204 0.413
8 0.03 0.7645 0.0495 0.935 2.20 0.334 0.448
9 0.04 0.72 0.126 0.894 2.22 0.342 0.459
10 0.01 0.8262 0.0108 10.476 2.41 0.347 0.430
11 0.04 0.624 0.042 0.72 2.01 0.291 0.337
12 0.07 0.402 0.042 0.528 1.87 0.252 0.305




GVIKP 1 0.014 0.868 0.049 1.316 3.15 0.271 0.402
2 0.077 0.861 0.077 1.239 3.00 0.261 0.387
3 0.098 0.84 0.049 1.204 3.30 0.284 0.380
4 0.014 1.162 0.07 1.61 2.86 0.401 0.538
5 0.02 1.27 0.15 0.84 2.75 0.455 0.360
6 0 1.056 0 1.04 2.81 0.376 0.370
7 0 1.24 0.016 1.1 3.37 0.368 0.331
(continued on next page)
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Table 5 (continued )
Treatment group Rats Fb1 (g) Fc K (g) Fb2 (g) Fc N (g) AW (mg) Fc K (g/mg) Fc N (g/mg)




GE 1 0.04 0.979 0.0825 1.094 2.42 0.388 0.486
2 0.02 0.715 0.044 0.902 1.61 0.457 0.588
3 0.0495 0.891 0 1.144 2.02 0.417 0.566
4 0.0162 0.6696 0.1134 0.8748 2.30 0.284 0.430
5 0.1 0.476 0.413 0.826 2.85 0.132 0.435
6 0.24 0.567 0.287 0.623 2.00 0.164 0.455




GEþVIKP 1 0.012 0.69 0.06 0.768 2.73 0.257 0.303
2 0.0616 0.6496 0.028 0.6216 2.44 0.241 0.266
3 0.03 0.78 0.115 0.855 2.79 0.290 0.348
4 0.028 0.8008 0.056 0.9968 2.60 0.297 0.405
5 0.02 1.2 0.11 0.75 2.70 0.437 0.319
6 0.01 1.05 0.11 0.642 3.13 0.339 0.240




S. Suarez et al. / Data in brief 29 (2020) 10516810then cut into 2 mm long rings. Assay was performed according to [3]. The rings were gently suspended
between two stainless steel wires in a water-jacketed organ baths kept at 37 C and filled with saline
solution, bubbled with a mixture of 5% CO2 and 95% O2, giving a pH of 7.40. The lower wirewas fixed to
a vertical plastic rod immersed in the organ bath, while the upper one was rigidly connected to a force
transducer (Grass FT.03D, Grass Telefactor, West Warwick, CT, USA). Preparations were then stretched
to obtain a passive force of 2 g and stabilized during 1 h, changing the solution in the chamber every 20
min. Tissue rings were then exposed to a solution containing 80mM potassium or norepinephrine 106
M. For each condition, the contractile responsewas recorded. At the end of the experiment, tissue rings
were dried on filter paper andweighed on a precision scale. The contraction intensity was calculated as
the quotient between strength and the weight of the ring (mgF/mg).
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